Eric Schmidt


Ultragenyx Pharmaceutical Inc (RARE) Tumbles on Ace-ER Failure; Top Analyst Remains Bullish

Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM

Let’s Hear It for Biogen Inc (BIIB) Drug Spinraza’s Blockbuster Potential, Raves Cowen Top Analyst

Coming off its successful launch of Spinraza, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), Biogen Inc …

This Top Analyst Sees Incyte Corporation (INCY) Shares Have Significant Upside Ahead

After Incyte Corporation (NASDAQ:INCY) announced positive clinical pipeline updates that had investors celebrating and shares soaring 9%, top analyst Eric Schmidt at Cowen …

Cowen Top Analyst Weighs In On Merrimack Pharmaceuticals Inc (MACK) Following Cancer Drugs Deal with Ipsen

In a research report released today, Cowen analyst Eric Schmidt reiterated a Market Perform rating on shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), after …

Celgene Corporation (CELG) Financial Outlook Remains Solid: Cowen

Celgene Corporation (NASDAQ:CELG) presented at JPM this morning, providing guidance updates and top-line FY2016 results. While FY2016 top-line results were slightly below expectations, …

Ionis Pharmaceuticals Inc (IONS), Akcea Strike Favorable Deal with Novartis AG (ADR) (NVS): Cowen Top Analyst

Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares were initially up 6% this morning after the biotech firm and its wholly-owned subsidiary Akcea Therapeutics signed an …

Cowen Skeptical on Biogen Inc (BIIB) Following Promotion of Chief Commercial Officer Michel Vounatsos to CEO

Biogen Inc (NASDAQ:BIIB) has decided to promote from within, opting to transition Chief Commercial Officer Michel Vounatsos into the role of CEO, a …

This Top Analyst Cheers Loxo Oncology Inc (LOXO) Clinical Progress as Shares Soar 26%

Loxo Oncology Inc (NASDAQ:LOXO) gave investors cause to celebrate today, to the tune of shares rocketing 26%, after providing an encouraging regulatory update …

Cowen Cautiously Optimistic on Ionis Pharmaceuticals Inc (IONS) as it Circles Approval in SMA

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its third-quarter report today as well as offered a clinical update. In reaction, Cowen analyst Eric Schmidt notes …

Cowen Sings the Praises of Exelixis, Inc. (EXEL) Following Robust First Full Quarter of Cabometyx Sales

As Exelixis, Inc.’s (NASDAQ:EXEL) “impressive launch continues” for its pipeline drug Cabometyx, approved to treat second-line advanced renal cell carcinoma (RCC), the most …